FLUODIAMON

Ultra-high resolution and ultra-sensitive fluorescence methods for objective sub-cellular diagnosis of early disease and disease progression in breast and prostate cancer

 Coordinatore KUNGLIGA TEKNISKA HOEGSKOLAN 

 Organization address address: Valhallavaegen 79
city: STOCKHOLM
postcode: 10044

contact info
Titolo: Ms.
Nome: Monica
Cognome: Thorén
Email: send email
Telefono: +46 8 55378103
Fax: +46 8 55378216

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 5˙542˙587 €
 EC contributo 4˙197˙774 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-06-01   -   2012-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KUNGLIGA TEKNISKA HOEGSKOLAN

 Organization address address: Valhallavaegen 79
city: STOCKHOLM
postcode: 10044

contact info
Titolo: Ms.
Nome: Monica
Cognome: Thorén
Email: send email
Telefono: +46 8 55378103
Fax: +46 8 55378216

SE (STOCKHOLM) coordinator 0.00
2    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Nome: Linda
Cognome: Ouwerkerk
Email: send email
Telefono: +3171526 9400
Fax: +3171526 8275

NL (LEIDEN) participant 0.00
3    BECKER & HICKL GMBH

 Organization address address: NAHMITZER DAMM 30
city: BERLIN
postcode: 12277

contact info
Titolo: Dr.
Nome: Wolfgang
Cognome: Becker
Email: send email
Telefono: 49307875632
Fax: 49307875734

DE (BERLIN) participant 0.00
4    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

 Organization address address: UNIVERSITAETSSTRASSE 1
city: DUSSELDORF
postcode: 40225

contact info
Titolo: Mr.
Nome: Uwe
Cognome: Droste
Email: send email
Telefono: 492118000000
Fax: 492118000000

DE (DUSSELDORF) participant 0.00
5    HELSINGIN YLIOPISTO

 Organization address address: YLIOPISTONKATU 4
city: HELSINGIN YLIOPISTO
postcode: 14

contact info
Titolo: Ms.
Nome: Katariina
Cognome: Vainio-Mattila
Email: send email
Telefono: +358 9 191 25043
Fax: +358 9 191 25044

FI (HELSINGIN YLIOPISTO) participant 0.00
6    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Riitta
Cognome: Perttunen-Elo
Email: send email
Telefono: +46 8 517 758 78
Fax: +46 8 517 706 90

SE (STOCKHOLM) participant 0.00
7    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Mr.
Nome: Manfred
Cognome: Messerschmidt
Email: send email
Telefono: 495512000000
Fax: 495512000000

DE (MUENCHEN) participant 0.00
8    NEODYNAMICS AB

 Organization address address: ULVSUNDAVAGEN 181
city: BROMMA
postcode: 16867

contact info
Titolo: Mr.
Nome: Peter
Cognome: Sellei
Email: send email
Telefono: +46 706242189

SE (BROMMA) participant 0.00
9    SENSL TECHNOLOGIES LIMITED

 Organization address address: BUILDING 6800 AVENUE 6000 CORK AIRPORT BUSINESS PARK
city: CORK
postcode: -

contact info
Titolo: Dr.
Nome: John
Cognome: Murphy
Email: send email
Telefono: +353 21 4350442
Fax: +353 21 4350447

IE (CORK) participant 0.00
10    TURUN YLIOPISTO

 Organization address address: YLIOPISTONMAKI
city: TURUN YLIOPISTO
postcode: 20014

contact info
Titolo: Dr.
Nome: Eliisa
Cognome: Särkilahti
Email: send email
Telefono: 35823336155
Fax: 35823336446

FI (TURUN YLIOPISTO) participant 0.00
11    UNIVERSITAET SIEGEN

 Organization address address: HERRENGARTEN 3
city: SIEGEN
postcode: 57072

contact info
Titolo: Prof.
Nome: Karl Heinz
Cognome: Drexhage
Email: send email
Telefono: 492717000000
Fax: 492717000000

DE (SIEGEN) participant 0.00
12    UNIVERSITAET ZU LUEBECK

 Organization address address: RATZEBURGER ALLEE 160
city: LUEBECK
postcode: 23538

contact info
Titolo: Ms.
Nome: Gabriele
Cognome: Huhn
Email: send email
Telefono: +49 451 5003307
Fax: +49 451 5003016

DE (LUEBECK) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

minimally    bioinformatic    patients    malignant    needle    microscopy    resolution    biomarkers    spatial    fine    disease    breast    cells    diagnostic    penetration    molecule    optical    detection    tumour    cell    quantitative    sampling    seeding    imaging    safe    validation    conclusive    exploited    fna    invasive    cancer    prostate    cyclin    material    stage    proteins    amounts    her    small    protocols    fluorescence    samples    aspiration    validated    anti    cellular    diagnosis    individual    cancers   

 Obiettivo del progetto (Objective)

'The overall objective of this proposal is to develop and validate a quantitative, minimally invasive diagnostic tool for early and conclusive detection, diagnosis and monitoring of disease and disease progression of breast and prostate cancer. A methodology will be developed making use of a combination of the probably most exciting recent advances in the field of light microscopy, for fluorescence-based optical imaging of individual sample cells. It includes advances which will take the spatial resolution far beyond the fundamental limits of optical resolution, the sensitivity down to an ultimate single-molecule level, and multi-parameter detection schemes significantly increasing the fluorescence information by which these cellular images can be analysed. Apart from detecting and identifying tumour markers in the samples, tumour-specific spatio-temporal molecular distributions within the intact sample cells will be exploited. This is to date an almost unexploited dimension of diagnostic information. By combining and supporting these novel optical methods with state-of-the-art affinity molecule biotechnology, , tumor biomarkers, fluorophore chemistry, and bioinformatic validation tools, all possible means will be exploited to extract a maximum amount of information out of very small amounts of sample material. We thereby expect that an improved, early and reliable diagnosis of breast and prostate cancer will be possible, from amounts of sample material small enough that a minimally invasive procedure such as Fine-needle aspiration (FNA) can be used. In addition, by the minimally invasive FNA-based sampling, serious sampling-related side-effects, such as seeding and spread of cancer cells can be completely avoided. Given the high incidence of breast and prostate cancer, and the utmost importance of an early and conclusive diagnosis for the prognosis of these diseases, the relevance of this project can not be overestimated.'

Introduzione (Teaser)

Early stage detection of breast and prostate cancer is crucial in order to further increase the survival rate of these patients. The EU funded a research initiative aimed at realising early breast and prostate cancer diagnosis using novel imaging and sampling methodologies that are safe and minimally invasive.

Descrizione progetto (Article)

Core needle biopsy used for sample collection carries the risk of cancer seeding due to trauma from needle penetration at the tumour site. Although, fine needle aspiration (FNA) cell sampling is minimally invasive, less risky, faster and cost efficient, sample quantity is often too sparse for conclusive results.

The FLUODIAMON project aimed to develop early cancer detection protocols that are safe and effective. This involved optimising the FNA sampling technique and image acquisition, resolution and specificity, identifying cancer biomarkers and standardising bioinformatics processing after validation.

Researchers developed FNA sampling needles with better ultrasound visibility for accurate positioning. Penetration and manoeuvrability were improved by adding computer-controlled oscillations and bevelling the needle tip. The results were validated based on data from more than 200 breast cancer patients. A fully functional anti-seeding instrument with a specialised anti-seeding needle was also developed and validated on patients.

Biomarkers found useful for the developed protocols and showing specific imaging features for breast and prostate cancer include vimentin and tubulin (cytoskeletal proteins), IGF1R, HER1, HER2 (membrane proteins), and Cyclin A and Cyclin E (cell cycle regulating proteins). Their spatial distribution patterns were studied in individual FNA sampled cells for the detection of malignant tumours.

Stimulated emission depletion (STED) microscopy and multi-parameter fluorescence detection imaging (MFDi) methods were developed for the study of sub-cellular FNA samples. For this purpose, highly photostable and bright fluorophores were used as labels and coupled to relevant protein biomarkers in imaging procedures.

Through bioinformatic quantitative analysis and verification, six independent diagnostic classifiers of malignant cancers were identified for their early detection. Knowledge gained was disseminated through 24 peer-reviewed articles, workshops and seminars, as well as on the website. Project members also applied for 10 specific patents.

The results from this project have opened the doors for safer, patient-friendly, minimally invasive early stage diagnostic and therapeutic treatment of most cancers. These methodologies could also be adapted for follow up of pre-malignant lesions or evaluating disease progress and response to therapy.

Altri progetti dello stesso programma (FP7-HEALTH)

T-CONTROL (2013)

Donor T Cells for Immune Control

Read More  

RARE-BESTPRACTICES (2013)

Platform for sharing best practices for management of rare diseases

Read More  

EUROGENTEST2 (2011)

"Genetic testing in Europe - Network for the further development, harmonization, validation and standardization of services"

Read More